CN105579472B - 新型抗体框架 - Google Patents

新型抗体框架 Download PDF

Info

Publication number
CN105579472B
CN105579472B CN201480036689.1A CN201480036689A CN105579472B CN 105579472 B CN105579472 B CN 105579472B CN 201480036689 A CN201480036689 A CN 201480036689A CN 105579472 B CN105579472 B CN 105579472B
Authority
CN
China
Prior art keywords
nucleic acid
sequence
human
antibody
framework region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480036689.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN105579472A (zh
Inventor
塞巴斯蒂安·迈耶
大卫·乌雷奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Numa Therapeutic Co ltd
Original Assignee
Numab AG
Health Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numab AG, Health Tech Co Ltd filed Critical Numab AG
Priority to CN202111136784.7A priority Critical patent/CN113943366B/zh
Publication of CN105579472A publication Critical patent/CN105579472A/zh
Application granted granted Critical
Publication of CN105579472B publication Critical patent/CN105579472B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201480036689.1A 2013-06-26 2014-06-26 新型抗体框架 Active CN105579472B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111136784.7A CN113943366B (zh) 2013-06-26 2014-06-26 新型抗体框架

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13003264.2 2013-06-26
EP13003264 2013-06-26
PCT/EP2014/001730 WO2014206561A1 (en) 2013-06-26 2014-06-26 Novel antibody frameworks

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111136784.7A Division CN113943366B (zh) 2013-06-26 2014-06-26 新型抗体框架

Publications (2)

Publication Number Publication Date
CN105579472A CN105579472A (zh) 2016-05-11
CN105579472B true CN105579472B (zh) 2021-10-22

Family

ID=48699516

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480036689.1A Active CN105579472B (zh) 2013-06-26 2014-06-26 新型抗体框架
CN202111136784.7A Active CN113943366B (zh) 2013-06-26 2014-06-26 新型抗体框架

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111136784.7A Active CN113943366B (zh) 2013-06-26 2014-06-26 新型抗体框架

Country Status (12)

Country Link
US (3) US10174102B2 (enExample)
EP (1) EP3013864A1 (enExample)
JP (4) JP6708544B2 (enExample)
KR (4) KR20220029763A (enExample)
CN (2) CN105579472B (enExample)
AU (2) AU2014301629B2 (enExample)
CA (1) CA2914829A1 (enExample)
HK (1) HK1218549A1 (enExample)
IL (3) IL243311B (enExample)
NZ (1) NZ714320A (enExample)
SG (2) SG10201811017QA (enExample)
WO (1) WO2014206561A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL243311B (en) 2013-06-26 2022-07-01 Numab Therapeutics AG New frameworks for antibodies
IL293435B1 (en) 2015-06-15 2026-04-01 Numab Therapeutics AG Heterodimeric multispecific antibody format
US20190048085A1 (en) 2016-02-25 2019-02-14 Cell Medica Switzerland Ag Modified cells for immunotherapy
IL261098B2 (en) 2016-03-17 2024-09-01 Numab Therapeutics AG Antibodies against TNF-ALPHA and their functional fragments
DK3219726T3 (da) 2016-03-17 2020-12-07 Tillotts Pharma Ag Anti-TNF-alfa-antistoffer og funktionelle fragmenter deraf
EP3430041B1 (en) 2016-03-17 2023-05-24 Numab Innovation AG Anti-tnfalpha-antibodies and functional fragments thereof
US10774140B2 (en) 2016-03-17 2020-09-15 Numab Therapeutics AG Anti-TNFα-antibodies and functional fragments thereof
PL3219727T3 (pl) 2016-03-17 2021-05-17 Tillotts Pharma Ag Przeciwciała anty-TNF alfa i ich funkcjonalne fragmenty
GB201621591D0 (en) * 2016-12-19 2017-02-01 Ucb Biopharma Sprl Antibody molecules and method
EP3634998B8 (en) 2017-06-05 2025-04-09 Numab Therapeutics AG Anti-cd3 epsilon antibodies
SG11201911527QA (en) 2017-06-05 2020-01-30 Numab Therapeutics AG Hetero-dimeric multi-specific antibody format targeting at least cd3 and hsa
MA49249A (fr) 2017-06-05 2021-04-14 Numab Therapeutics AG Nouveaux anticorps anti-hsa
WO2018224441A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
WO2018224439A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
US20200157224A1 (en) * 2017-06-25 2020-05-21 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
KR102763369B1 (ko) 2017-06-25 2025-02-05 시스트이뮨, 인코포레이티드 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도
EP3459968A1 (en) * 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations
EP4591879A3 (en) 2019-01-31 2025-10-22 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
CA3203552A1 (en) * 2020-12-30 2022-07-07 Ascendo Biotechnology, Inc. Monoclonal antibody against human mac-1 and uses thereof
WO2022171771A1 (en) 2021-02-12 2022-08-18 Boehringer Ingelheim International Gmbh Complement c3 antigen binding proteins
EP4305190A4 (en) 2021-03-11 2025-03-26 Iggenix, Inc. METHODS AND SYSTEMS FOR PREDICTING AN ALLERGIC REACTION
CR20240265A (es) 2021-12-22 2024-10-16 Boehringer Ingelheim Int Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
JP2025542567A (ja) * 2022-11-04 2025-12-26 ミンク セラピューティクス，インコーポレイティッド Ｂ細胞成熟抗原（ｂｃｍａ）キメラ抗原受容体インバリアントナチュラルキラーｔ細胞及びその用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155726A2 (en) * 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc Humanization of rabbit antibodies using a universal antibody framework
WO2009155723A2 (en) * 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
AU2003259718A1 (en) 2003-08-07 2005-03-07 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
WO2008004834A1 (en) 2006-07-06 2008-01-10 Isu Abxis Co., Ltd Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor
FR2910896B1 (fr) * 2006-12-29 2012-11-16 Lab Francais Du Fractionnement Anticorps monoclonal dirige contre le recepteur humain des ldl
KR20170036814A (ko) 2007-05-21 2017-04-03 앨더바이오 홀딩스 엘엘씨 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
BRPI0813645A2 (pt) 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
BRPI0914251B1 (pt) * 2008-06-25 2022-07-19 Novartis Ag Imunoligante recombinante, seu fragmento de ligação ao antígeno, uso dos mesmos, e composição
US8193235B2 (en) 2009-06-12 2012-06-05 University Of Kansas Compositions and methods for establishing and maintaining stem cells in an undifferentiated state
BR112012027917A2 (pt) * 2010-04-30 2017-11-28 Alexion Pharma Inc anticorpos que apresentam reduzida imunogenicidade em um indivíduo humano
EP2726504A1 (en) * 2011-05-27 2014-05-07 Dutalys Antibodies with improved folding stability
IL243311B (en) 2013-06-26 2022-07-01 Numab Therapeutics AG New frameworks for antibodies
EP3459968A1 (en) 2017-09-20 2019-03-27 Numab Innovation AG Novel stable antibody variable domain framework combinations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155726A2 (en) * 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc Humanization of rabbit antibodies using a universal antibody framework
WO2009155723A2 (en) * 2008-06-25 2009-12-30 Esbatech, An Alcon Biomedical Research Unit Llc STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering;S Ewert等;《Methods》;20041001;第34卷(第2期);全文 *
Generic Approach for the Generation of Stable Humanized Single-chain Fv Fragments from Rabbit Monoclonal Antibodies;Leo Borras等;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;20100319;第285卷(第12期);第9055页左栏第2段和右栏"Framework Selection"部分 *
HUMANIZATION OF AN ANTI-P185HER2 ANTIBODY FOR HUMAN CANCER THERAPY;P Carter等;《PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES》;19920515;第89卷(第10期);全文 *

Also Published As

Publication number Publication date
CN105579472A (zh) 2016-05-11
KR102286053B1 (ko) 2021-08-04
US10174102B2 (en) 2019-01-08
US20160130326A1 (en) 2016-05-12
SG11201509899PA (en) 2016-01-28
JP2022028659A (ja) 2022-02-16
IL313351B1 (en) 2026-01-01
AU2014301629A1 (en) 2015-12-10
WO2014206561A1 (en) 2014-12-31
IL243311A0 (en) 2016-03-31
IL243311B (en) 2022-07-01
JP2024026176A (ja) 2024-02-28
US20190119359A1 (en) 2019-04-25
KR20220029763A (ko) 2022-03-08
JP2016523537A (ja) 2016-08-12
HK1218549A1 (zh) 2017-02-24
JP6708544B2 (ja) 2020-06-10
AU2020202770B2 (en) 2023-01-05
AU2020202770A1 (en) 2020-05-14
EP3013864A1 (en) 2016-05-04
CA2914829A1 (en) 2014-12-31
SG10201811017QA (en) 2019-01-30
US20230212265A1 (en) 2023-07-06
AU2014301629B2 (en) 2020-02-06
IL293477B2 (en) 2024-11-01
WO2014206561A8 (en) 2016-02-18
JP2019201643A (ja) 2019-11-28
KR20160024923A (ko) 2016-03-07
KR20240000622A (ko) 2024-01-02
IL293477B1 (en) 2024-07-01
IL313351A (en) 2024-08-01
CN113943366A (zh) 2022-01-18
US11427628B2 (en) 2022-08-30
IL293477A (en) 2022-08-01
NZ714320A (en) 2022-02-25
KR20210097829A (ko) 2021-08-09
CN113943366B (zh) 2024-12-13

Similar Documents

Publication Publication Date Title
CN105579472B (zh) 新型抗体框架
JP2023115024A (ja) 新規の安定した抗体の可変領域フレームワークの組み合わせ
JP2016523537A5 (enExample)
EP3183272B1 (en) Asymmetric multispecific antibodies
US10738103B2 (en) Antibody light chains
EP3634997B1 (en) Anti-hsa antibodies
HK40023336B (en) Anti-hsa antibodies
HK40023336A (en) Anti-hsa antibodies
HK1205145B (en) Improved antibody light chains

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Vaden Weir, Switzerland

Applicant after: NUMAB INNOVATION AG

Address before: Vaden Weir, Switzerland

Applicant before: NUMAB AG

CB02 Change of applicant information
CB02 Change of applicant information

Address after: Vaden Weir, Switzerland

Applicant after: The Health Technology Co.,Ltd.

Address before: Vaden Weir, Switzerland

Applicant before: NUMAB INNOVATION AG

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: Vaden Weir, Switzerland

Patentee after: Numa Therapeutic Co.,Ltd.

Country or region after: Switzerland

Address before: Vaden Weir, Switzerland

Patentee before: The Health Technology Co.,Ltd.

Country or region before: Switzerland